This morning Khiron Life Sciences Corp (TSXV: KHRN) announced they received the status of National Interest Strategic Project by the Government of Colombia. This certification enables Khiron to simplify authorization processes, reduce costs, and accelerate time to market for their services and products for the domestic market of Colombia and for export of finished products.
The National Interest Strategic Project certification was established to prioritize the development of specific projects/companies that are deemed by the Government to be able to significantly increase the national economy. This certification immediately simplifies and accelerates the administration and ability to process execution of strategic projects in Colombia. Under the plan, Khiron aims to register and introduce more than 4 SKU’s in the Medical Cannabis Category and at least 10 SKU’s in the Consumer Packaged Goods Category.
According to the official company press release, ‘Khiron is one of three companies to obtain this status, placing the Company at the forefront of the industry in Colombia.’
This morning it was also announced that PharmaCielo received the same status.
Khiron shares last traded at 49.5c on the TSXV at the time of publishing.
FULL DISCLOSURE: Khiron Life Sciences is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Khiron Life Sciences on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.
